-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Bicara Therapeutics, Lowers Price Target to $44

Benzinga·04/07/2025 11:22:02
Listen to the news
HC Wainwright & Co. analyst Robert Burns maintains Bicara Therapeutics (NASDAQ:BCAX) with a Buy and lowers the price target from $45 to $44.